Quick Answer
PDS Biotechnology Corp reported Cash and Equivalents of $26.71 million for fiscal year 2025.
PDS Biotechnology Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $26.71M | -35.9% |
| 2024 | $41.69M | -26.3% |
| 2023 | $56.56M | -23.4% |
| 2022 | $73.82M | +13.1% |
| 2021 | $65.24M | +126.2% |
| 2020 | $28.84M | +137.1% |
| 2019 | $12.16M | +11628.4% |
| 2018 | $103.7K | -99.9% |
| 2017 | $88.07M | -17.2% |
| 2016 | $106.40M | -18.3% |
| 2015 | $130.19M | +848.3% |
| 2014 | $13.73M | +74.7% |
| 2013 | $7.86M | +5475.8% |
| 2011 | $140.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.20M | -47.3% | -17.8% |
| June 30, 2025 | $31.87M | -44.8% | -20.3% |
| March 31, 2025 | $39.98M | -40.0% | -4.1% |
| December 31, 2024 | $41.69M | -26.3% | -16.2% |
| September 30, 2024 | $49.75M | -8.3% | -13.8% |
| June 30, 2024 | $57.73M | -4.8% | -13.4% |
| March 31, 2024 | $66.63M | +2.2% | +17.8% |
| December 31, 2023 | $56.56M | -23.4% | +4.3% |
- PDS Biotechnology Corp showed a decrease of -35.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, PDS Biotechnology Corp’s cash and equivalents has grown by 18853.7% (from $140.9 thousand to $26.71 million).
- The most recent figure is from PDS Biotechnology Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: